Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.

@article{Hofbauer2001ReceptorAO,
  title={Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.},
  author={Lorenz Christian Hofbauer and Andreas Neubauer and Armin E. Heufelder},
  journal={Cancer},
  year={2001},
  volume={92 3},
  pages={460-70}
}
BACKGROUND The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappaB ligand (RANKL), its receptor, receptor activator of nuclear factor-kappaB (RANK), and its decoy receptor, osteoprotegerin (OPG), on osteoclast biology and bone resorption. Furthermore, it highlights the impact of these compounds on the pathogenesis… CONTINUE READING